← feed

Is NCT03146065 results overdue?

Yes — results are overdue. Primary completion was 2018-05-03; the FDAAA-801 reporting deadline (2019-05-03) passed 2652 days ago and no results are posted on ClinicalTrials.gov.

Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of PF-06730512

NCT IDNCT03146065 ↗
SponsorPfizer (INDUSTRY)
Public issuerPFIZER INC — PFE (CIK 0000078003) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-05-03 (ACTUAL)
Reporting deadline2019-05-03 (completion + 365d)
Days overdue2652
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 d29d9b98dc379e09… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03146065. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →